Skip to content

Efficacy of Dalfyra (extended release Fampridine) in fatigue in multiple sclerosis patients

Efficacy of Dalfyra (extended release Fampridine) in fatigue in multiple sclerosis patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210429051129N1
Enrollment
88
Registered
2021-06-07
Start date
2021-06-22
Completion date
Unknown
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue in patients with multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Patients in the intervention group are given Famperidine (Delfyra 10 mg ) (from Cinnagen Pharmaceutical Company) twice daily for three months. Intervention 2: Contr

Sponsors

Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with MS over the age of 18 who have not taken Dalfyra for the past year. Patients have The Expanded Disability Status Scale (EDSS) below 7

Exclusion criteria

Exclusion criteria: Patients have a kidney problem or a history of seizures. Patients who are allergic to this drug. Patients who have had an acute attack in the last 3 months.

Design outcomes

Primary

MeasureTime frame
Fatigue score based on modified fatigue impact scale (MFIS) questionnaire. Timepoint: Both groups complete the Fatigue score based on modified fatigue impact scale (MFIS) questionnaire at the beginning of the study and three months later. Method of measurement: Based on the Fatigue score based on modified fatigue impact scale (MFIS) questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShirin Mavandadi

Qazvin University of Medical Sciences

sh.mavandadi@qums.ac.ir+98 28 3332 6033

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026